ISCO develop a parthenogenesis stem cell technology which could potentially avoid the limiting immune-response issues in regenerative medicine.
Researchers demonstrate that inhibiting microglial activation could be a potential strategy for restoring the disrupted dopamine transmission linked to mental health disorders, such as anxiety and depression.
A study monitoring the brain activity of two patients with amyotrophic lateral sclerosis provides insight into how neurons control muscle movement in humans.
A novel PET scanning technique that utilizes an immune stimulant and a radioactive label has been demonstrated to accurately measure the immune response in the brain.
A novel population health management program for older adults has achieved significant health improvement for individuals with depression and reductions in stress for caregivers of dementia patients.
Asterias Biotherapeutics, Inc. has commenced a Phase 1/2a trial evaluating escalating doses of AST-OPC1 in newly injured patients with sensory and motor complete cervical spinal cord injury.
New research has presented an innovative imaging technology that could reduce the risk associated with brain tumor removal by providing surgeons with a color-coded map of a patient’s brain.
A new method for classifying low and intermediate grade gliomas has recently been reported in the in the New England Journal of Medicine. This new approach could lead to improvements in diagnosis, treatment and potentially patient outcomes.